Cardiac surgery in children with trisomy 13 or trisomy 18: How safe is it?

JTCVS Open

Division of Cardiothoracic Surgery, Department of Surgery, Emory University School of Medicine and Pediatric Cardiac Surgery, Children's Healthcare of Atlanta at Egleston, Atlanta, Ga.

Published: December 2022


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Objective: Surgery for heart defects in children with trisomy 13 or 18 is controversial. We analyzed our 20-year experience.

Methods: Since 2002, we performed 21 operations in 19 children with trisomy 13 (n = 8) or trisomy 18 (n = 11). Age at operation was 4 days to 12 years (median, 154 days). Principal diagnosis was ventricular septal defect in 10 patients, tetralogy of Fallot in 7 patients, arch hypoplasia in 1 patient, and patent ductus arteriosus in 1 patient.

Results: The initial operation was ventricular septal defect closure in 9 patients, tetralogy of Fallot repair in 7 patients, pulmonary artery banding in 1 patient, patent ductus arteriosus ligation in 1 patient, and aortic arch/coarctation repair in 1 patient. There were no operative or hospital deaths. Median postoperative intensive care and hospital stays were 189 hours (interquartile range, 70-548) and 14 days (interquartile range, 8.0-37.0), respectively, compared with median hospital stays in our center for ventricular septal defect repair of 4.0 days and tetralogy of Fallot repair of 5.0 days. On median follow-up of 17.4 months (interquartile range, 6.0-68), 1 patient was lost to follow-up after 5 months. Two patients had reoperation without mortality. There have been 5 late deaths (4 with trisomy 18, 1 with trisomy 13) predominately due to respiratory failure from 4 months to 9.4 years postoperatively. Five-year survival was 66.6% compared with 24% in a group of unoperated patients with trisomy 13 or 18.

Conclusions: Cardiac operation with an emphasis on complete repair can be performed safely in carefully selected children with trisomy 13 or trisomy 18. Hospital resource use measured by postoperative intensive care and hospital stays is considerably greater compared with nontrisomy 13 and 18.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9801274PMC
http://dx.doi.org/10.1016/j.xjon.2022.09.005DOI Listing

Publication Analysis

Top Keywords

children trisomy
16
trisomy trisomy
12
ventricular septal
12
septal defect
12
tetralogy fallot
12
hospital stays
12
interquartile range
12
trisomy
10
patients tetralogy
8
patient patent
8

Similar Publications

Pulmonary hypertension is common in children with Trisomy 21, frequently with multifactorial aetiologies. Registry data provide better understanding of disease development, diagnostic workup and treatment patterns in children with Trisomy 21. TOPP (Tracking Outcomes and Practice in Pediatric Pulmonary Hypertension) is a centre-based, comprehensive registry.

View Article and Find Full Text PDF

Background: Non-invasive prenatal testing (NIPT) has demonstrated robust performance in detecting common trisomies and copy number variations. However, its clinical utility for rare chromosomal abnormalities (RCAs) remains controversial due to low positive predictive value (PPV).

Methods: This study retrospectively analyzed the data of 94,125 cases that underwent NIPT at Ganzhou Maternal and Child Health Hospital in China.

View Article and Find Full Text PDF

Background: Administrative claims data are used in clinical studies; however, recorded diagnoses and procedures have not been fully validated for pediatric patients. We aimed to examine the validity of recorded information on pediatric patients in the Japanese Diagnosis Procedure Combination (DPC) database, a national inpatient database that includes administrative claims data.

Methods: We validated the DPC data using medical charts as the reference standard.

View Article and Find Full Text PDF

Background: Most patients with trisomy 18 (18T) die of cardiac or other severe anomalies within the first few years. Although surgical intervention for cardiac lesions or other diseases has improved these patients' prognoses in recent years, some survivors face the risk of developing neoplasms, such as hepatoblastoma. However, the treatment strategy remains controversial because of the poor prognosis.

View Article and Find Full Text PDF

Percutaneous Thoracic Duct Externalization and Autotransfusion in Patients With Lymphatic Failure Due to Elevated Central Venous Pressure.

Circ Cardiovasc Interv

September 2025

Division of Cardiology (Y.D., E.P., L.B., M.J.G., R.C., J.T., M.L.O.B., D.V., A.G.D.W., E.F., R.S., J.J.R., C.L.S.), Children's Hospital of Philadelphia, PA.

Background: External drainage of the thoracic duct can temporarily reduce tissue congestion and improve symptoms in patients with heart failure. However, loss of fluid limits the duration of this approach. Here, we report on our initial experience with thoracic duct drainage and autotransfusion in patients with elevated central venous pressure.

View Article and Find Full Text PDF